Short Wave Folgen

The FDA has approved a new drug for Alzheimer's. But a lot of experts are skeptical about whether the drug works. Rhitu Chatterjee talks with science correspondent Jon Hamilton about the controversial drug aducanumab and why the U.S. Food and Drug Administration approved it. For more of Jon's reporting, read "For Those Facing Alzheimer's, A Controversial Drug Offers Hope."You can email Short Wave at ShortWave@NPR.org.To manage podcast ad preferences, review the links below:See pcm.adswizz.com for information about our collection and use of personal data for sponsorship and to manage your podcast sponsorship preferences.Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

The past year has been the driest or second driest in most Southwestern U.S. states since record-keeping began in 1895. Climate Correspondent Lauren Sommer reports that farms and cities have begun imposing water restrictions, but the water supply will shrink no matter what the weather brings. The supply spans tens of millions of people and the farmland that produces most of the country's fruits and vegetables. As a result, the people who manage the West's complex water systems are realizing that with climate change, they can no longer rely on the past to predict the future. Read more of Lauren's reporting.Email us at shortwave@npr.org.To manage podcast ad preferences, review the links below:See pcm.adswizz.com for information about our collection and use of personal data for sponsorship and to manage your podcast sponsorship preferences.Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

Health Correspondent Allison Aubrey updates us on the Biden Administration's goal to have 70 percent of U.S. adults vaccinated by the July 4. Plus, as vaccine makers plan for the possibility that COVID-19 vaccine boosters will be needed, they're pushing ahead with research into new-generation flu shots and mRNA cancer vaccines. Questions? Existential dread? Optimism? We'd love to hear it — write us at shortwave@npr.org.To manage podcast ad preferences, review the links below:See pcm.adswizz.com for information about our collection and use of personal data for sponsorship and to manage your podcast sponsorship preferences.Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy